Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Study summary

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedRMC-6291 and RMC-6236

Plus 5 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · KRAS · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 19, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?98 U.S. locations

Locations may change over time.

Who runs it?Revolution Medicines, Inc.

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1 / Phase 2
Sponsor: Revolution Medicines, Inc.
Interventions being studied: Drug: RMC-6291; Drug: RMC-6236; Drug: Pembrolizumab; Drug: Cisplatin; Drug: Carboplatin; Drug: Pemetrexed; Drug: RMC-9805

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Metastatic or stage IV→

Biomarkers

KRAS→

Treatment approach

Immunotherapy→Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

All Patients (unless otherwise noted):
≥ 18 years of age
ECOG PS is 0 to 1
Adequate organ function as outlined by the study
Received prior standard therapy appropriate for tumor type and stage
Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)
Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)
Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)

Reasons someone may not be able to joinExclusion criteria

All Patients:
Primary central nervous system (CNS) tumors
Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
Major surgery \< 28 days of first dose
Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids Other inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Banner MD Anderson Cancer CenterGilbert, Arizona
City of Hope - DuarteDuarte, California
City of Hope - LennarIrvine, California
University of California Los AngelesLos Angeles, California
UC Davis, Davis Comprehensive Cancer CenterSacramento, California
University of California, San Diego Moores Cancer CenterSan Diego, California
UCSF Medical Center - Mission BaySan Francisco, California
Stanford University - Stanford Cancer InstituteStanford, California
Kaiser PermanenteVallejo, California
Georgetown University Medical CenterWashington D.C., District of Columbia
Boca Raton Clinical Research AssociatesPlantation, Florida
Cancer Specialists of North FloridaSaint Augustine, Florida

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 19, 2026. Always confirm current availability with the study team.

View original record ↗